NL-OMON31335撤回3 期
Dose-reduced versus standard conditioning followed by allogeneic stem cell Transplantation in patients with MDS or sAML: A randomised phase III study - alloRIC in MDS
European Group for Blood and Marrow Transplantation (EBMT) tav Prof. Dr. T. de Witte0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Cytogenetically proven MDS or sAML
- •Patient between 18 and 60 years of age in case of a HLA matched unrelated donor
- •Patient between 50 and 65 years of age in case of a HLA matched related donor
排除标准
- •Blasts >20% in bone marrow at time of transplantation
- •Patients with a life-expectancy of less than six months because of another debilitating disease
- •Invasive fungal infection at time of registration
研究者
相似试验
进行中（未招募）
1 期
Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study (RICMAC) - RICMAC MDS/sAMde novo-MDS, treatment-induced MDS (T MDS), AML arising from MDS, treatment-induced AMLMedDRA version: 9.1 Level: PT Classification code 10000880 Term: Acute myeloid leukaemiaMedDRA version: 9.1 Level: LLT Classification code 10028533 Term: Myelodysplastic syndromeEUCTR2005-002011-24-GBEuropean Group for Blood and Marrow Transplantation160
进行中（未招募）
不适用
Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study (RICMAC) - RICMAC MDS/sAMde novo-MDS, treatment-induced MDS (T MDS), AML arising from MDS, treatment-induced AMLMedDRA version: 9.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2005-002011-24-BEEuropean Group for Blood and Marrow Transplantation160
进行中（未招募）
不适用
Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study - RICMACMyelodysplastic syndromes and secondary acute myeloid leukaemiaEUCTR2005-002011-24-FIEuropean Group for Blood and Marrow Transplantation (EBMT)160
终止
3 期
Dose-reduced Versus Standard Conditioning in MDS/sAMLMyelodysplastic SyndromesSecondary Acute Myeloid LeukemiaNCT01203228European Society for Blood and Marrow Transplantation129
已完成
不适用
Randomised controlled study of dose reduction and withdrawal strategies of adalimumab and etanercept in rheumatoid arthritis: saving costs at what expense?chronic arthritis10023213rheumatoid arthritisNL-OMON38325Sint Maartenskliniek180